Results Of A Dutch Cost-Effectiveness Model Of Radium-223 In Comparison To Cabazitaxel, Abiraterone, And Enzalutamide In Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Docetaxel
| Verfasser: | |
|---|---|
| Dokumenttyp: | Artikel |
| Erscheinungsdatum: | 2015 |
| Reihe/Periodikum: | Value in Health ; volume 18, issue 7, page A459 ; ISSN 1098-3015 |
| Verlag/Hrsg.: |
Elsevier BV
|
| Schlagwörter: | Public Health / Environmental and Occupational Health / Health Policy |
| Sprache: | Englisch |
| Permalink: | https://search.fid-benelux.de/Record/base-27021836 |
| Datenquelle: | BASE; Originalkatalog |
| Powered By: | BASE |
| Link(s) : | http://dx.doi.org/10.1016/j.jval.2015.09.1184 |
